Ray Alvarez

At Imprint Labs, I lead research initiatives focused on developing cutting-edge immune profiling tools to accelerate personalized diagnostics and therapeutics for autoimmune diseases. Our mission is to decode complex immune histories and gain insights into autoimmunity, enabling faster and more accurate identification of disease mechanisms and therapeutic targets.

My academic research focused on understanding immune responses to viral infections, specifically characterizing HIV-1 and SARS-CoV-2 pathogenesis, as well as antibody-mediated immune responses. For these studies, I developed and optimized several novel assays to investigate neutralizing and non-neutralizing antibody-mediated effector responses (e.g., ADCC) and the immune mechanisms that contribute to viral control in chronic infections.

As Co-Founder and CEO of Ichor Biologics, I led the development of a novel platform to produce human monoclonal antibodies for treating infectious diseases. Our innovative platform isolates high-affinity, pathogen-specific antibodies derived from convalescent patients, aiming to accelerate therapeutic development and provide safe, clinically effective treatments for global health challenges.